PMID- 26886301
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20211203
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Linking)
VI  - 105
IP  - 4
DP  - 2016 Apr
TI  - Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
PG  - 1454-66
LID - S0022-3549(15)00008-8 [pii]
LID - 10.1016/j.xphs.2015.10.007 [doi]
AB  - Suboptimal chemotherapy of anticancer drugs may be attributed to a variety of 
      cellular mechanisms, which synergize to dodge the drug responses. Nearly 2 
      decades of heat-shock protein 90 (Hsp90)-targeted drug discovery has shown that 
      the mono-therapy with Hsp90 inhibitors seems to be relatively ineffective 
      compared with combination treatment due to several cellular dodging mechanisms. 
      In this article, we have tried to analyze and review the Hsp90 and mammalian 
      target of rapamycin (m-TOR)-mediated drug resistance mechanisms. By using this 
      information we have discussed about the rationale behind use of drug combinations 
      that includes both or any one of these inhibitors for cancer therapy. Currently, 
      biodegradable nano vector (NV)-loaded novel drug delivery systems have shown to 
      resolve the problems of poor bioavailability. NVs of drugs such as paclitaxel, 
      doxorubicin, daunorubicin, and others have been successfully introduced for 
      medicinal use. Hence, looking at the success of NVs, in this article we have also 
      discussed the progress made in the delivery of biodegradable NV-loaded Hsp90 and 
      m-TOR-targeted inhibitors in multiple drug combinations. We have also discussed 
      the possible ways by which the market success of biodegradable NVs can positively 
      impact the clinical trials of anti-Hsp90 and m-TOR combination strategy.
CI  - Copyright (c) 2016 American Pharmacists Association(R). Published by Elsevier Inc. 
      All rights reserved.
FAU - Rochani, Ankit K
AU  - Rochani AK
AD  - Bio Nano Electronics Research Centre, Graduate School of Interdisciplinary 
      Science, Toyo University, Kawagoe, Saitama-350-8585, Japan.
FAU - Ravindran Girija, Aswathy
AU  - Ravindran Girija A
AD  - Bio Nano Electronics Research Centre, Graduate School of Interdisciplinary 
      Science, Toyo University, Kawagoe, Saitama-350-8585, Japan.
FAU - Borah, Ankita
AU  - Borah A
AD  - Bio Nano Electronics Research Centre, Graduate School of Interdisciplinary 
      Science, Toyo University, Kawagoe, Saitama-350-8585, Japan.
FAU - Maekawa, Toru
AU  - Maekawa T
AD  - Bio Nano Electronics Research Centre, Graduate School of Interdisciplinary 
      Science, Toyo University, Kawagoe, Saitama-350-8585, Japan.
FAU - Sakthi Kumar, D
AU  - Sakthi Kumar D
AD  - Bio Nano Electronics Research Centre, Graduate School of Interdisciplinary 
      Science, Toyo University, Kawagoe, Saitama-350-8585, Japan. Electronic address: 
      sakthi@toyo.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151223
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HSP90 Heat-Shock Proteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Drug Discovery
MH  - Drug Resistance, Neoplasm
MH  - HSP90 Heat-Shock Proteins/*antagonists & inhibitors/*metabolism
MH  - Humans
MH  - Models, Molecular
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/metabolism
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/*metabolism
OTO - NOTNLM
OT  - biomaterials
OT  - cancer
OT  - cancer chemotherapy
OT  - drug resistance
OT  - nanoparticles
OT  - nanotechnology
EDAT- 2016/02/18 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/02/18 06:00
PHST- 2015/07/16 00:00 [received]
PHST- 2015/09/16 00:00 [revised]
PHST- 2015/10/12 00:00 [accepted]
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0022-3549(15)00008-8 [pii]
AID - 10.1016/j.xphs.2015.10.007 [doi]
PST - ppublish
SO  - J Pharm Sci. 2016 Apr;105(4):1454-66. doi: 10.1016/j.xphs.2015.10.007. Epub 2015 
      Dec 23.